database / gh-secretagogue
Tesamorelin
also known as Egrifta
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 16137828. Carbons are implicit vertices, hydrogens on carbon suppressed. Every atom sits where PubChem placed it.
Sequence
Primary structure not characterised in the public record.
GHRH(1-44) analogue bearing an N-terminal trans-3-hexenoyl group; the acyl modification places it outside plain one-letter representation here.
Molecular data
| molecular formula | C221H366N72O67S |
|---|---|
| molecular weight | 5136 Da (PubChem) |
| computed backbone mass | not characterised |
| length | not characterised |
| net charge (pH 7.4) | not characterised |
| mean hydropathy | not characterised |
| half-life | not characterised |
| delivery route | subcutaneous |
| PubChem CID | 16137828 |
| PDB | not characterised |
| UniProt parent | P01286 |
Mechanism
GHRH analogue; approved for HIV-associated lipodystrophy.
Reported targets: GHRHR
Experimental structure
No experimental structure deposited in the PDB. A predicted fold is not a structure, so nothing is drawn.
Parent protein
Based on full-length GHRH(1-44). UniProt P01286 · 108 aa
Reported effects
Each row is an outcome described in the literature indexed for this peptide.
| reported outcome | where it appears |
|---|---|
| visceral fat reduction | P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence i… Open forum infectious diseases 2026 |
| IGF-1 elevation | Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV… BMJ open 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT01579695 | Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® | TERMINATED | — |
| NCT01264497 | Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes | COMPLETED | PHASE2 |
| NCT03226821 | Body Composition and Adipose Tissue in HIV | TERMINATED | PHASE4 |
| NCT01591902 | Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® | TERMINATED | PHASE4 |
| NCT01632592 | Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Horm | WITHDRAWN | NA |
Literature (8)
P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants — Open forum infectious diseases 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol — BMJ open 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42419889 · DOI 10.1136/bmjopen-2026-120740
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Preprints.org 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · DOI 10.20944/preprints202512.1011.v3
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports medicine (Auckland, N.Z.) 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41966639 · DOI 10.1007/s40279-026-02437-0
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials — Obesity research & clinical practice 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41545261 · DOI 10.1016/j.orcp.2026.01.002
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Preprints.org 2025
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · DOI 10.20944/preprints202512.1011.v1
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists — Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42139091 · DOI 10.1093/cid/ciag121
Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis — Journal of the International Association of Providers of AIDS Care 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42538058 · DOI 10.1177/23259582261475549
The mechanism, illustrated
Related
Ipamorelin
gh-secretagogue · 8 citations
CJC-1295
gh-secretagogue · 8 citations
Sermorelin
gh-secretagogue · 8 citations
GHRP-2
gh-secretagogue · 8 citations
GHRP-6
gh-secretagogue · 7 citations
Hexarelin
gh-secretagogue · 8 citations